Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT1000 Phase III in Healthy Women 18-45 Years
NCT06041061Phase 3Active, not recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Aug 2023
- Primary completion
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant 14-valent human papillomavirus vaccine in human papillomavirus infection, Cervical Cancer (CC), vulvar cancer, vaginal cancer, anal cancer, sponsored by Sinocelltech Group Limited. Started Aug 2023; status: active, not recruiting.
02
Drugs
recombinant 14-valent human papillomavirus vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)vulvar cancervaginal canceranal cancer
Beyond the preview
Go deeper on NCT06041061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041061.